Amazing grant news for the whole lab with multiple fundable R01 scores + Raquel's SPORE CEP funded!

What a few months the lab has had! Not one but TWO R01s received fundable scores, including a 1st percentile mPI grant between Katherine, Raquel, and our colleague Dr. Nadine Hempel,

Raquel also received funding for her new ovarian cancer project through the Pitt SPORE Career Enhancement Program!

Needless to say, we are hiring! Check out our projects and email us if you are interested in joining the team.

Naveen's and Raquel's paper on de novo purine metabolism as a vulnerability of p16low cancers is out!

Congratulations to co-first authors Drs. Naveen Kumar Tangudu and Raquel Buj for this very nice study on a metabolic vulnerability in p16low cancers. Using multiple CRISPR screens and omics-based approaches, they identified de novo purine synthesis to be upregulated in p16low cancer cells. They also found that targeting this axis using anti-folates decreased proliferation of these cells both in vitro and in vivo. You can read the full text here: https://aacrjournals.org/cancerrescommun/article/doi/10.1158/2767-9764.CRC-23-0450/743061/De-novo-purine-metabolism-is-a-metabolic

New preprint on alpha-ketoglutarate and histone acetylation- congrats Dr. Apoorva Uboveja and co-authors

We are excited to share our newest preprint from 1st author Dr. Apoorva Uboveja. In this project, she found something totally unexpected- aKG affects histone acetylation through carnitine synthesis. This axis promoted DNA repair by homologous recombination. These data provide new evidence for a metabolically-sensitive epigenetic axis that could be targeted for cancer therapy. They also show that methylation is not the only epigenetic change that is affected by aKG. https://www.biorxiv.org/content/10.1101/2024.02.06.578742v1

New preprint alert! First authors Naveen and Raquel identify anti-folates as a strategy to treat cancers with p16 loss

Congrats to co-first authors Drs. Naveen Kumar Tangudu and Raquel Buj on their new preprint. Using CRISPR screens and pharmacological approaches, they identified purine metabolism as a metabolic vulnerability of p16-low cancers. Read more here: https://www.biorxiv.org/content/10.1101/2023.07.15.549149v2